---
layout: category
title: Lecture- Understanding Schizophrenia
permalink: /osher/DiverseMinds/schizophrenia/
baseurl: ""
published: true
---
<style>
.floating-nav {
  position: relative; /* No longer fixed */
  top: 0;
  left: 0;
  width: 100%; /* Full width of the page */
  background-color: #f8f9fa; /* Background color */
  border-bottom: 1px solid #ccc; /* Border at the bottom */
  padding: 10px 20px; /* Padding inside the bar */
  box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1); /* Optional shadow */
  z-index: 1000;
  display: flex; /* Makes it horizontal */
  justify-content: space-around; /* Distribute links evenly */
  align-items: center; /* Center align the text vertically */
}

.floating-nav a {
  text-decoration: none;
  color: #007bff; /* Link color */
  font-size: 1rem;
  padding: 0 10px; /* Space around each link */
}

.floating-nav a:hover {
  color: #0056b3; /* Hover color */
  text-decoration: underline;
}
</style>
<div class="floating-nav">
  <a href="/osher/DiverseMinds/coursegoals/">Main Page</a>
  <a href="/osher/DiverseMinds/brainbasics/">üß† Brain Basics</a>
  <a href="/osher/DiverseMinds/alzheimers/">üü™ Alzheimer's</a>
  <a href="/osher/DiverseMinds/parkinsons/">üå∑ Parkinson's</a>
  <a href="/osher/DiverseMinds/depression/"><strong>  ö;…û </strong> Depression</a>
  <a href="/osher/DiverseMinds/ptsd/">üü¶ PTSD</a>
  <a href="/osher/DiverseMinds/schizophrenia/">‚¨ú Schizophrenia</a>
</div>

<div style="border: 2px solid purple; padding: 10px; background-color: #f9f4ff; border-radius: 5px; margin: 10px 0;">
Schizophrenia is one of the most challenging mental health conditions to understand, despite over a century of research and countless studies. While we have made advances, such as identifying genetic risks, brain network differences, and effective early interventions, there is still no clear consensus on its exact nature. In fact, some experts now question whether schizophrenia is a valid concept at all, suggesting it might need to be redefined or replaced entirely. This ongoing debate highlights the importance of regularly reviewing what we truly know about the disorder and reconsidering how we understand it.
</div>

## Objectives  
By the end of this lecture, students should be able to:  
- Understand the basic biology of brain function and neurotransmission relevant to Schizophrenia.  
- Define Schizophrenia and understand its epidemiology.  
- Describe the neurobiology and pathology of Schizophrenia.  
- Discuss the clinical symptoms, diagnosis, and course of the disease.  
- Explore treatment options, including pharmacological and non-pharmacological interventions.  
- Discuss what we know and what remains unknown about Schizophrenia.  
- Examine current research trends and future directions in Schizophrenia treatment.  
---
Summary Video on Schizophrenia:
<iframe width="560" height="315" src="https://www.youtube.com/embed/pjTmZqBNB78?si=y-wiL1pMQXTMwCny" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
---

## 1. Basic Biology of Brain Function and Neurotransmission  
- **Neural Circuits in the Brain**:  
   - The brain relies on intricate circuits involving neurons, synapses, and neurotransmitters for cognition, perception, and behavior.  
   - Key regions affected in Schizophrenia include:  
      - **Prefrontal Cortex**: Important for reasoning, decision-making, and social behavior.  
      - **Hippocampus**: Critical for memory formation.  
      - **Thalamus**: Relays sensory and motor signals.  

- **Neurotransmitters and Schizophrenia**:  
   - **Dopamine Hypothesis**:  
      - Schizophrenia is associated with hyperactive dopamine signaling in certain brain pathways (mesolimbic pathway).  
   - **Glutamate Dysfunction**:  
      - Abnormal glutamatergic activity in the NMDA receptor may contribute to cognitive and negative symptoms.  
   - **Other Neurotransmitters**: Serotonin and GABA also play a role in Schizophrenia.  

---

## 2. Introduction to Schizophrenia  
- **Definition**:  
   - Schizophrenia is a chronic, severe mental disorder characterized by disturbances in thought, perception, emotion, and behavior.  
- **History**:  
   - Term coined by Eugen Bleuler in 1911, meaning ‚Äúsplit mind‚Äù (not to be confused with split personality).  
- **Epidemiology**:  
   - Affects ~1% of the global population.  
   - Onset typically occurs in late adolescence or early adulthood (18-25 for men; 25-35 for women).  
   - Equal prevalence across genders but differences in age of onset.  

### **What We Know**  
- Schizophrenia is a global health challenge, affecting individuals in all cultures.  
- It tends to emerge during critical developmental periods (late adolescence).  

### **What We Don‚Äôt Know**  
- The precise combination of genetic, neurodevelopmental, and environmental factors that triggers onset.  

---

## 3. Neurobiology and Pathology of Schizophrenia

### **Dopaminergic System**
The dopamine system plays a crucial role in regulating mood, motivation, and cognition. In schizophrenia, it is thought to operate abnormally, leading to distinct groups of symptoms:  
- **Mesolimbic Pathway Overactivity**: This pathway connects the midbrain to the limbic system, which is involved in emotion and reward processing. Overactivity in this area is linked to **positive symptoms**, such as hallucinations, delusions, and disorganized thinking. These symptoms are often the most visible and distressing aspects of the condition.  
- **Prefrontal Cortex Underactivity**: The prefrontal cortex is critical for higher-level functions, like decision-making, planning, and emotional regulation. Reduced dopamine activity in this area is associated with **negative symptoms**, including a lack of motivation, social withdrawal, and blunted emotions. These symptoms are harder to detect but significantly impair quality of life and functional outcomes.

### **Structural Brain Changes**
Advances in brain imaging techniques have revealed significant structural differences in individuals with schizophrenia:  
- **Enlarged Ventricles**: Ventricles are fluid-filled spaces in the brain, and their enlargement suggests a loss of surrounding brain tissue. This reduction is seen as evidence of neurodegeneration or developmental abnormalities.  
- **Gray Matter Reduction**: Specific areas of the brain, including the **prefrontal cortex**, **hippocampus**, and **temporal lobes**, show a decrease in gray matter volume. These regions are involved in executive functions, memory, and language, explaining some of the cognitive and perceptual challenges faced by individuals with schizophrenia. These structural changes may also worsen as the illness progresses.

### **Neurodevelopmental Hypothesis**
There is evidence that schizophrenia may originate long before symptoms appear, rooted in abnormalities during brain development:  
   - During prenatal and early childhood stages, factors such as maternal infections, malnutrition, or exposure to stress may disrupt normal brain maturation.  
   - These disruptions could lead to subtle changes in brain structure and function, which remain dormant until adolescence or early adulthood‚Äîperiods marked by significant brain remodeling and stress, often coinciding with the first onset of symptoms.  

### **Glutamate Hypothesis**
Glutamate, the brain's primary excitatory neurotransmitter, is increasingly recognized as a key player in schizophrenia:  
- Reduced function of **NMDA receptors**, which are essential for glutamate signaling, can impair communication between neurons. This disruption may contribute to cognitive deficits, such as memory problems and difficulties in attention and learning.  
- While dopamine dysregulation is traditionally emphasized, the glutamate hypothesis provides an additional layer of complexity, suggesting that schizophrenia may involve a broader network of neurotransmitter imbalances.

---

### **What We Know**
- Schizophrenia involves a complex interplay of **dopamine dysregulation** and **structural brain abnormalities**. These features contribute to the diverse range of symptoms, from hallucinations to cognitive deficits.  
- Early life factors, including disruptions in brain development, are likely critical in setting the stage for the illness.  
- The involvement of glutamate highlights that schizophrenia is not limited to a single neurotransmitter system, suggesting broader dysfunction in how brain cells communicate.

### **What We Don‚Äôt Know**
- The root causes of the initial changes in brain chemistry and structure remain unclear. Are they genetic, environmental, or a combination of both?  
- The exact role of **glutamate dysfunction** and how it interacts with dopamine dysregulation in disease onset is still under investigation.  
- Why schizophrenia manifests so differently among individuals‚Äîboth in symptom severity and response to treatment‚Äîcontinues to be a significant question in the field.

These insights emphasize that schizophrenia is not a single, uniform disorder but a constellation of symptoms and mechanisms that likely require personalized approaches to treatment and intervention.

---

## 4. Clinical Symptoms and Diagnosis  
- **Positive Symptoms** (Excess or distortion of normal functions):  
   - Hallucinations (auditory most common).  
   - Delusions (false beliefs, e.g., persecution or grandeur).  
   - Disorganized speech and behavior.  

- **Negative Symptoms** (Reduction or loss of normal functions):  
   - Avolition: Lack of motivation.  
   - Anhedonia: Reduced ability to experience pleasure.  
   - Alogia: Reduced speech output.  
   - Flat affect: Diminished emotional expression.  

- **Cognitive Symptoms**:  
   - Impaired memory, attention, and executive function.  

- **Diagnosis**:  
   - Clinical evaluation based on **DSM-5 criteria**:  
      - Presence of symptoms for at least 6 months with functional impairment.  
   - Differential diagnosis: Must exclude mood disorders, substance use, and medical conditions.  

### **What We Know**  
- Symptoms are categorized into positive, negative, and cognitive domains.  
- Diagnosis relies on clinical interviews and observed behavior.  

### **What We Don‚Äôt Know**  
- How to develop objective biomarkers for diagnosis.  
- Why symptom severity and progression vary widely across individuals.  

The progression of symptomology
(Figure from Tandon et al. (2024)- pdf distributed)
<a 
    href="https://www.osmosis.org/" 
    target="_blank" 
    title="Image from Tandon et al." 
    style="text-decoration: none;">
    <img 
        src="https://ars.els-cdn.com/content/image/1-s2.0-S0920996423004279-gr2.jpg" 
        alt="This image is from Tandon et al. showing the progression of the illness." 
        style="width: 100%; max-width: 600px; height: auto;" />
</a>


---

## 5. Treatment and Management  

### A. Pharmacological Treatments  
- **Antipsychotic Medications**:  
   - First-generation (Typical): Target dopamine receptors (e.g., Haloperidol).  
      - Effective for positive symptoms but causes motor side effects.  
   - Second-generation (Atypical): Act on dopamine and serotonin (e.g., Risperidone, Clozapine).  
      - Better for negative symptoms with fewer motor side effects.  

### B. Non-Pharmacological Interventions  
- **Cognitive Behavioral Therapy (CBT)**: Helps manage delusions and hallucinations.  
- **Social Skills Training**: Improves daily functioning and communication.  
- **Family Therapy**: Supports families and reduces relapse rates.  
- **Lifestyle Interventions**: Exercise, diet, and sleep regulation to support overall mental health.  

### **What We Know**  
- Antipsychotics are effective for managing positive symptoms.  
- Psychosocial interventions improve outcomes and quality of life.  

### **What We Don‚Äôt Know**  
- How to treat cognitive and negative symptoms effectively.  
- Why some patients are treatment-resistant, even to advanced therapies.  
> ## Treatment of Schizophrenia: 
> ### **Medications for Schizophrenia**
> - Schizophrenia is primarily treated with medications that target dopamine receptors. These include:  
>   - **D2 Receptor Antagonists**: Traditional antipsychotics that block dopamine activity, effective in reducing psychotic symptoms like hallucinations.  
>   - **D2 Receptor Partial Agonists**: Newer medications (e.g., aripiprazole, brexpiprazole) that partially adjust dopamine activity, providing similar benefits with fewer side effects.  
> - While these medications are effective at managing core psychotic symptoms, they have limited impact on negative symptoms (e.g., lack of motivation) and cognitive difficulties (e.g., memory problems).  
> - All antipsychotics, except **clozapine**, have similar effectiveness, but they differ in their side effects. Clozapine stands out for treating severe symptoms that don‚Äôt respond to other medications and reducing suicidal thoughts.  
> - **Second-generation antipsychotics** have advanced treatment by reducing movement-related side effects seen with older medications.
> ### **Psychological and Social Treatments**
> - Combining medication with therapy and support improves outcomes:  
>   - **Cognitive Behavioral Therapy (CBT)**: Helps reduce psychotic symptoms like delusions.  
>   - **Family Therapy**: Reduces relapse rates by involving families in treatment.  
>   - **Social Skills Training and Psychoeducation**: Boosts everyday functioning and coping skills.  
> - These treatments are particularly effective when started early in the illness, especially during the first psychotic episode.
> ### **New Developments in Treatment**
> 1. **Non-Dopaminergic Medications**:  
>    - Research is moving beyond dopamine-focused drugs. New treatments target other brain systems, such as acetylcholine and glutamate, to address negative symptoms and cognitive challenges.  
>    - Promising medications, like **Kar-XT** (currently under FDA review), may soon offer new options for patients.
> 2. **Early Intervention Programs**:  
>    - Early treatment after the first psychotic episode, such as coordinated specialty care, improves long-term outcomes.  
>    - Efforts to identify and treat people in the early stages of psychosis (before full symptoms develop) aim to delay or prevent the onset of schizophrenia.
> 3. **Focus on Recovery**:  
>    - The ultimate goal is to help people with schizophrenia lead fulfilling, meaningful lives.  
>    - Recovery-focused care emphasizes shared decision-making, individualized treatment goals, and access to comprehensive support services.
> ### **Key Takeaway**
> Treating schizophrenia involves more than just managing symptoms. Medications, therapies, and new approaches work together to improve quality of life, with a growing focus on early intervention and helping individuals achieve their personal goals for recovery.

---

## 6. Current Research and Future Directions  
- **Neurobiology**:  
   - Investigating the role of glutamate and NMDA receptor dysfunction.  
- **Genetics**:  
   - Identification of risk genes (e.g., DISC1, COMT) and polygenic influences.  
- **Biomarkers**:  
   - Developing brain imaging and blood tests for early diagnosis.  
- **Novel Therapies**:  
   - NMDA receptor modulators, anti-inflammatory agents, and stem cell therapies.  
- **Precision Medicine**:  
   - Personalized treatment approaches based on genetic and neurobiological profiles.  

### **What We Know**  
- Genetic and environmental factors both contribute to Schizophrenia.  
- Advanced imaging helps understand brain structure and connectivity changes.  

### **What We Don‚Äôt Know**  
- How to translate emerging therapies into effective clinical treatments.  
- Whether early intervention can prevent or reverse disease progression.  

---

## 7. Summary and Key Takeaways  
- Schizophrenia is a severe mental disorder characterized by positive, negative, and cognitive symptoms.  
- Neurotransmitter imbalances (dopamine, glutamate) and structural brain changes are central to the pathology.  
- Current treatments focus on symptom management but do not address the underlying causes.  
- Research efforts aim to uncover biomarkers, new therapies, and personalized treatment strategies.  

---

## 8. Discussion Questions  
1. Why is Schizophrenia considered a neurodevelopmental disorder?  
2. Discuss the strengths and limitations of the dopamine hypothesis.  
3. How might glutamatergic therapies revolutionize the treatment of Schizophrenia?  
4. Why are cognitive and negative symptoms more challenging to treat?  
5. What role do genetic and environmental factors play in Schizophrenia risk?  

---

Long and great descriptive video on SZ:
<iframe width="560" height="315" src="https://www.youtube.com/embed/0zHU6fiM2KY?si=SJtLnUYb0JxAIW3_" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>

---
## References   
- **Articles**:  
   - Howes, O. D., & Murray, R. M. (2014). Schizophrenia: An integrated sociodevelopmental-cognitive model. *The Lancet*, 383(9929), 1677-1687.  
   - Tandon, R., Nasrallah, H., Akbarian, S., Carpenter, W. T., DeLisi, L. E., Gaebel, W., Green, M. F., Gur, R. E., Heckers, S., Kane, J. M., Malaspina, D., Meyer-Lindenberg, A., Murray, R., Owen, M., Smoller, J. W., Yassin, W., & Keshavan, M. (2024). The schizophrenia syndrome, circa 2024: What we know and how that informs its nature. Schizophrenia Research, 264, 1-28. https://doi.org/10.1016/j.schres.2023.11.015
- **Websites**:  
   - National Institute of Mental Health: [www.nimh.nih.gov](https://www.nimh.nih.gov)  
   - Schizophrenia International Research Society: [www.schizophreniaresearchsociety.org](https://www.schizophreniaresearchsociety.org)  
   - https://www.mcleanhospital.org/essential/schizophrenia *Great website!*
